CKD stages 2-4 patients with hyperuricemia
Conditions
Interventions
Experimental group:Febuxostat tablets
Sponsors
Xinhua Hospital Affiliated To Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged between 18 and 70 years male or female; 2. CKD 2-4 stage (15 420 mumol /L (7.0mg/dl); 4. Patients who have been diagnosed with CKD2~4 for more than half a year and have complete renal function data recorded for more than half a year; 5. Sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. In the acute active phase of gout (the group can be enrolled after 2 weeks of symptom control in the acute phase); 2. Patients with acute kidney injury and acute nephritis; 3. Patients with active liver disease or abnormal liver function (the upper limit of ALT or AST is more than 2.5 times of normal value);A history of cirrhosis, decompensated cirrhosis, or a history of hepatic encephalopathy; 4. Patients with a history of hypertension failed to control their blood pressure effectively after antihypertensive medication (systolic blood pressure > 160mmHg and/or diastolic blood pressure > 105mmHg) 5. BMI>=30kg/m2; 6. Patients had a history of active malignant tumor within 3 months before screening; 7. Patients had acute coronary syndrome or cerebrovascular disease (cerebral hemorrhage, cerebral infarction or subarachnoid hemorrhage, etc.); 8. Diagnosed as diabetic kidney disease (DKD); 9. Active tuberculosis and latent tuberculosis infection, who are treated with isoniazid, pyrazinamide and other anti-tuberculosis drugs; 10. Long-term use of the following drugs is under use or planned during the study period: continuous treatment with glucocorticoids (oral or intravenous) for more than two weeks, immunosuppressants (e.g., cyclosporine A, tacrolimus, rapamycin, mycopherate, leflumide, azathioprine, thioprine);But not including tripterygium wilfordii preparation), estrogen replacement therapy, biological agents (anti-thymoglobulin, CD3 monoclonal antibody or polyclonal antibody); 11. Other drugs that seriously affect uric acid metabolism were determined by the researchers; 12. Kidney transplant recipients; 13. Have a history of allergy to febulostat or other xanthine oxidase inhibitors (such as allopurinol); 14. Women who are breast-feeding or pregnant, and those who plan to become pregnant within one year; 15. Other researchers were enrolled within 3 months before screening; 16. The researcher considers it inappropriate to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| eGFR; | — |
Secondary
| Measure | Time frame |
|---|---|
| 24hPRO;ACR;Blood pressure;sUA;BUN; | — |
Countries
China
Contacts
Public ContactJiang Gengru
Xinhua Hospital Affiliated To Shanghai Jiaotong University School of Medicine
Outcome results
None listed